Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
NCT05559879
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
37
Enrollment
OTHER
Sponsor class
Conditions
Gynecologic Cancer
Carcinoma
Uterine Cancer
Endometrial Cancer
Interventions
DRUG:
Cabo + Dostarlimab
Sponsor
University of Alabama at Birmingham